During fall of 2019 and beginning of 2020 GPX Medical participates in PWC’s program to scale up promising European Life Science companies, PWC Scale. GPX Medical was specially selected for the program and will together with PWC experts prepare the company for larger capital investments in 2020 to support the company’s process for CE-Mark and FDA approval for its product NEOLA, Neonatal Lung Analyser, 24 hour monitoring of the lung function of preterm born infants.

About GPX Medical

GPX Medical AB was formed in 2016 as a subsidiary to GASPOROX AB (publ), with the aim to develop and commercialize medical applications of GASMAS technology. The company is owned to 60% by GASPOROX AB (publ) and to 40% by Norsk Elektro Optikk AS, and located in Lund, Sweden. Org. nbr. 559069-9012.

For investors

Please contact CEO Hanna Sjöström for investment opportunities:
hs@gpxmedical.se

Contact

GPX Medical AB
Maskinvägen 1
223 70 Lund
Sweden
info@gpxmedical.se